Atrx loss as a promising screening tool for the identification of diffuse midline glioma subtype, H3K27/MAPKinase co-altered

Acta Neuropathol Commun. 2024 Jun 27;12(1):105. doi: 10.1186/s40478-024-01818-8.

Arnault Tauziède-Espariat^{1

2}, David Castel^{3

4}, Yassine Ajlil³, Lucie Auffret^{3

4}, Romain Appay⁵, Cassandra Mariet⁶, Lauren Hasty⁶, Alice Métais^{6

7}, Fabrice Chrétien^{6

7}, Jacques Grill^{7

3

8}, Pascale Varlet^{6

7}

¹ GHU Paris Psychiatrie Neurosciences, Department of Neuropathology, Sainte-Anne Hospital, 1, rue Cabanis, Paris, 75014, France. [email protected].
² Paris University France, Paris, 75006, France. [email protected].
³ U981, Molecular Predictors and New Targets in Oncology, INSERM, Gustave Roussy, Université Paris- Saclay, Villejuif, 94805, France.
⁴ Univ. Evry, Université Paris-Saclay, Evry, 91000, France.
⁵ Department of Pathology, APHM La Timone, Marseille, France.
⁶ GHU Paris Psychiatrie Neurosciences, Department of Neuropathology, Sainte-Anne Hospital, 1, rue Cabanis, Paris, 75014, France.
⁷ Paris University France, Paris, 75006, France.
⁸ Department of Pediatric Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.

No abstract available

Publication types